Manhattan judge rules for Novartis in Entresto patent dispute
- A federal judge in Manhattan ruled in favor of Novartis
- The ruling dismissed allegations of patent misuse
- The case concerned exclusivity on the heart-failure drug Entresto
- The decision was issued on Wednesday
*this image is generated using AI for illustrative purposes only.
A federal judge in Manhattan ruled in favor of Novartis on Wednesday, rejecting allegations that the company misused one of its patents to maintain exclusivity on its blockbuster heart-failure drug, Entresto.
The ruling addresses claims regarding the strategic use of intellectual property rights. The decision supports the pharmaceutical giant's position on its patent practices concerning the widely prescribed medication.
Historical Stock Returns for Novartis
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.56% | -5.46% | +30.19% | 0.0% | 0.0% | 0.0% |
How might this ruling influence the FDA's upcoming policy discussions on patent evergreening for other blockbuster drugs?
What are the potential impacts on Entresto's generic competition timeline and Novartis's long-term revenue projections?
Could this precedent encourage other pharmaceutical companies to adopt similar patent strategies for their top-selling medications?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
